Pancreatic Cancer: Early SBRT Shows Promise Before Chemoimmunotherapy
Pancreatic cancer remains one of the most difficult malignancies to treat, particularly when patients present with borderline resectable or locally advanced disease. In these cases, surgery is often…
Read the full articleYou might also wanna read
SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer
Conditions : Pancreatic Cancer Interventions : Drug: SBRT + Ipilimumab N01 + Sintilimab + AG Chemotherapy Sponsors : Shandong Cancer Hospita
Tumor-on-a-Chip Reveals How Pancreatic Cancer Hijacks Immune Cells
A new tumor-on-a-chip model shows how pancreatic cancer uses immune cells to survive and resist treatment.
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Researchers in Spain have developed a therapy protocol that could revolutionize the treatment of pancreatic cancer.
nypost.com·5mo ago
New Drug Shows Promise in Penetrating Pancreatic Cancer's 'Fibrotic Fortress'
For a long time, the likelihood of surviving pancreatic cancer has been extremely low.
sciencealert.com·1mo agoDaraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM
Results of the earlier phase 1-2 study of 168 patients, published recently 🧪💊
Promising pancreatic cancer drug may unlock new class of treatments targeting cancer's master switch
A promising drug could be the first of an entirely new class of treatments
economist.com·26d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.